Inhibitors of HER2/neu (erbB-2) signal transduction☆
References (32)
- et al.
The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
FEBS Lett
(1997) - et al.
The ErbB-2/HER-2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
Biochim Biophys Acta
(1998) - et al.
Biochemical and antiproliferative properties of 4-[ar(alk)yl-amino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor
Biochem Pharmacol
(1997) - et al.
Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
J Biol Chem
(1997) - et al.
Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires upregulation of p27KIP1 independent of MAP kinase activity
J Biol Chem
(2000) - et al.
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
Cell
(1989) - et al.
Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones, and interactions with neu
J Steroid Biochem
(1989) - et al.
Specificity within the EGF family/ErbB receptor family signaling network
Bioessays
(1998) - et al.
ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling
J Mammary Gland Biol Neopl
(1997) - et al.
Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER-2 block crosstalk with growth factor receptors
Oncogene
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
Cancer Res
Phase II study of weekly intravenous recombinant humanized anti-p185HER-2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer
J Clin Oncol
Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
J Clin Oncol
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
The humanized anti-HER-2 rhuMAB HER-2 mediates antibody-dependent cell-mediated cytotoxicity via FcγR III
Cited by (26)
Advanced gastric cancer - Slow but steady progress
2010, Cancer Treatment ReviewsCitation Excerpt :The first successful phase III trial of a targeted agent in combination with chemotherapy in advanced gastric cancer has recently been reported in patients with HER2-positive gastric cancer. Trastuzumab is a humanized IgG1 κ monoclonal antibody that binds to Her-2/neu, a growth factor receptor responsible for growth signalling and survival when amplified or over-expressed.35 It is part of the standard treatment for Her2 positive breast cancer, affording a survival advantage with chemotherapy in both the metastatic and adjuvant settings.
Kinases as targets in the treatment of solid tumors
2010, Cellular SignallingTreatment of HER2-positive metastatic breast cancer following initial progression
2009, Clinical Breast CancerEvaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B
2004, Biochimica et Biophysica Acta - General SubjectsResistance to trastuzumab: A necessary evil or a temporary challenge?
2002, Clinical Breast CancerConcordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma
2022, Indian Journal of Pathology and Microbiology
- ☆
Supported by National Institutes of Health Grant no. RO1 CA80195, a Clinical Investigator Award from the Department of Veterans Affairs, and Vanderbilt-Ingram Cancer Center support Grant no. CA68545.
- 1
Dr Arteaga has received research grant support from Bristol-Myers Squibb and Genentech. He has served on the speakers bureau for AstraZeneca and Genentech and has served as a paid consultant to Genentech.